Daniel R. Chevallard
CFO, Principal Financial & Accounting OfficerMr. Daniel R. Chevallard, also known as Dan, CPA, has been the Principal Financial Officer and Principal Accounting Officer at LENZ Therapeutics, Inc. He had been Chief Financial Officer of Viracta Therapeutics, Inc. since July 2019 until March 20, 2024 and served as its Secretary and Treasurer. He serves as the Chief Financial Officer of Lenz Therapeutics, Inc. since March 21, 2024. He served as Chief Operating Officer at Viracta Therapeutics, Inc. since March 2021 until March 20, 2024. Previously, Mr. Chevallard served as the Chief Financial Officer and principal financial officer at Regulus Therapeutics from May 2017 to July 2019. Mr. Chevallard joined Regulus Therapeutics in December 2012 as Vice President, Accounting and Financial Reporting and served as Vice President, Finance from May 2013 to April 2017. Prior to joining Regulus Therapeutics, Mr. Chevallard held various senior roles in corporate finance, accounting and financial reporting including Controller and Senior Director, Finance of Prometheus Laboratories Inc. (acquired by Nestlé Health Science in July 2011). Prior to joining Prometheus, Mr. Chevallard spent approximately five years in public accounting at Ernst & Young, LLP in their assurance services practice. He received his Bachelor of Accountancy from the University of San Diego and is a Certified Public Accountant in the state of California.
Positions
- Company NameLENZ Therapeutics, Inc.Stock CodeLENZPositionCFO, Principal Financial & Accounting OfficerColleagues
